All In Biotech

Drug Trial Radar · NCT02974725

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma

Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

241

Actual

Start

Feb 24, 2017

Primary completion

Apr 24, 2024

Study completion Apr 24, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

Conditions

  • Non-Small Cell Lung Cancer
  • Melanoma

Interventions

  • LXH254Drug

    LXH254 will be supplied as tablet for oral use.

  • LTT462Drug

    LTT462 will be supplied as hard gelatin capsule for oral use.

  • TrametinibDrug

    Trametinib will be supplied as film-coated tablet for oral use

  • RibociclibDrug

    Ribociclib will be supplied in tablets and hard gelatin capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs) as a measure of safety and tolerabilityTime frame: up to 5 years
  2. Dose limiting toxicities (DLTs) (dose escalation only)Time frame: up to 3 years
  3. Tolerability measured by the number of subjects who have interruptions/reductions of study treatment and reason for interruptions/reductionsTime frame: up to 5 years
  4. Tolerability measured by the dose intensity of study drug, Relative Dose intensity for subjects with non-zero duration of exposure is computed as the ratio of dose intensity and planned dose intentityTime frame: Up to 5 years

Locations

32 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California San Diego .

    San Diego, California

  • UCSF Medical Center

    San Francisco, California

  • Massachusetts General Hospital SC

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Ctr .

    New York, New York

  • Sarah Cannon Research Institute Tennessee Oncology

    Nashville, Tennessee

  • Uni of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Verona, VR, Italy

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Seville, Andalusia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Pamplona, Navarre, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.